blue of california

ambrisentan, oral (LETAIRIS)

Diagnosis Considered for Coverage: • Pulmonary Arterial Hypertension (PAH), WHO Group 1
Coverage Criteria: **For diagnosis listed above:** • WHO group 1 classification, **and** • Dose does not exceed 10 mg once daily.
Coverage Duration: one year

Effective Date: 11/29/2023